
    
      -  To capture the treatment patterns and clinical characteristics of patients with ER/PR
           positive, HER2-negative MBC in Greece

        -  To evaluate the outcome of patients per treatment line (objective response, progression
           free survival, time to disease progression per line of therapy), overall survival

        -  To record adverse events per line of therapy

        -  To recording of the causes of treatment discontinuation per line of therapy
    
  